148 results about "Lipidome" patented technology

The invention discloses retinol retinoate-ceramide lipidosome modified by hyaluronic acid and salts thereof and a preparation method of the retinol retinoate-ceramide lipidosome, and belongs to the technical field of cosmetic nano-carriers. The preparation method comprises the steps that retinol retinoate-ceramide lipidosome is prepared, hyaluronic acid is pretreated, and the hyaluronic acid and the salts thereof are combined to prepare the retinol retinoate-ceramide lipidosome. The liposome is modified by hyaluronic acid and salts thereof in a dual-mechanism manner, and purification and stabilization are realized; the preparation method of the retinol retinoate-ceramide liposome comprises the following steps: dissolving phospholipid, a functionalized lipid component with positive ions and amino functional groups, cholesterol, retinol retinoate and ceramide in absolute ethyl alcohol to serve as an organic phase, taking a phosphate buffer solution as a water phase, dropwise adding the organic phase into the water phase under a stirring condition, stirring, performing ultrasonic treatment, washing, and drying to obtain the retinol retinoate-ceramide liposome. Performing membrane extrusion to obtain a liposome suspension; the retinol retinoate-ceramide liposome modified by hyaluronic acid and salts thereof prepared by the invention has excellent stability, skin transmittance and anti-aging and moisturizing effects, also has low irritation, and is suitable for anti-aging cosmetics.

The invention discloses an aptamer-modified lipid nano delivery platform as well as a preparation method and application thereof, and belongs to the field of biomedicine. The platform is prepared by taking DPPC, DOTAP and cholesterol as basic lipid components, Ce6 as a sound-sensitive agent and Flt3L as an immune agonist, controlling the particle size through gradient extrusion, and coupling cholesterol with an EpCAM aptamer for surface modification. The method has the core advantages that active targeting enrichment of tumors is realized by virtue of the aptamer, tumor cell immunogen cell death (ICD) is induced in combination with a sonodynamic therapy (SDT), and damage-related molecular patterns (DAMPs) are released; meanwhile, Flt3L is released in a tumor microenvironment, collection and activation of type 1 classical dendritic cells (cDC1) are specifically promoted, an'endogenous cDC1 vaccine 'is constructed, and CD8 + T cell mediated anti-tumor immune response is enhanced. Experiments prove that the platform can significantly improve the cDC1 infiltration level of a tumor site, effectively inhibit the progress of prostate cancer (PCa), and provide a new normal form for immune'cold tumor 'treatment.

A combination of lipid-binding molecules and / or lipid-binding proteins with lipid components (i.e., mispids) is provided for use in modifying the interaction between target molecules and lipid membranes. This includes, for example, the use of lipid-binding molecules and / or mispids to improve the sequencing efficiency and throughput of nanopore-based sequencing systems. To sequence target molecules such as nucleic acid sequences or nucleic acid substitute polymers derived therefrom, lipid-binding molecules and / or their mispids are combined with the target molecules. The mixture is then applied to a nanopore-based sequencing chip. The target molecules are then sequenced in the presence of lipid-binding molecules and / or nanodiscs, thereby improving the capture, arrival time, and effective concentration of the target molecules across the chip membrane. Such improved efficiency is particularly beneficial, for example, when the concentration of the target molecule is low.

This invention discloses a gRNA combination and its application in the preparation of drugs for the prevention of metabolic-associated fatty liver disease (MASLD). The gRNA combination, when mixed with Cas9 protein, yields an RNP complex, which, when microinjected into mouse zygotes, can breed a stable and heritable mouse strain with TMEM68 gene knockout. Combining lipidomics, transcriptomics, and primary hepatocyte functional verification, the core regulatory role of TMEM68 in hepatic lipid metabolism is revealed for the first time systematically. Experiments demonstrate that TMEM68 deficiency significantly reduces the storage of triglycerides (TAG) in the liver and hepatocytes, decreases lipid droplet formation, and reshapes the metabolic homeostasis of various lipids such as glycerophospholipids, cholesterol esters, and bile acids. Therefore, the gRNA combination of this invention, or the RNP complex obtained by mixing the gRNA combination with Cas9 protein, can be used to prepare drugs for the prevention of MASLD, providing a novel intervention strategy for MASLD prevention with broad application prospects.

Relates to a lipid composition with targeting property, the lipid composition comprises an active component, a lipid carrier and a targeting component, and the components of the lipid carrier comprise a positively charged component and phospholipid. An active component is entrapped in a lipid carrier containing a component with positive charges, so that the surface of the lipid carrier has positive charges, then the lipid carrier and a targeting component with negative charges are mixed, and the targeting component is adsorbed on the surface of the drug-loaded lipid carrier with positive charges through an electrostatic adsorption effect, so that the drug-loaded lipid carrier which is high in transfection efficiency and good in transfection effect is prepared. The present invention relates to a lipid composition having a targeting property and a high targeting property. The invention relates to a lipid nanoparticle delivery system with high biological activity, tumor targeting property and good safety. The lipid nanoparticle delivery system comprises an active component, cationic lipid, ionizable lipid and neutral phospholipid. The active component is entrapped in the lipid nanoparticle containing the cationic lipid, the ionizable lipid and the neutral phospholipid, and when the molar ratio of the cationic lipid to the ionizable lipid is in a specific range, the lipid nanoparticle has higher biological activity, tumor targeting property and good safety.

Provided herein are novel ionizable cationic lipid compounds capable of assembling with other helper lipids, such as phospholipids, structural lipids, and polymer conjugated lipids, that are capable of reducing aggregation to form lipid nanoparticles for delivery of therapeutic RNA both in vitro and in vivo. These compounds contain a thiourea group (-NRc-C (S)-NRd-) in the linker between the lipid group and the head group.

The invention discloses a macrophage-targeting lipid nanoparticle and application thereof in malignant tumor treatment, ID3 mRNA is delivered through the lipid nanoparticle, firstly, an ID3 sequence is subjected to codon optimization to improve the expression efficiency and stability of ID3 protein, and the core treatment effect is enhanced; the lipid composition and the targeting ligand of the nanoparticles are further optimized, and mannose modified PEG lipid material (DSPE-PEG2000-Mannose) is specifically combined with the CD206 receptor on the surface of the macrophage, so that the targeting property and the transfection efficiency of the delivery system are remarkably improved. The ID3 mRNA is delivered to the macrophages by utilizing the lipid nanoparticles of the targeted macrophages, so that the tumor cells can be effectively swallowed and killed, the in-situ treatment of pancreatic cancer is realized, and better tumor inhibition and immune activation effects are achieved.

The invention discloses a production process of lipid nanoparticles entrapped with weak-acid and weak-hydrophobicity small molecule drugs, which comprises the following steps: S1, preparing a water phase and an organic phase, the organic phase comprising a lipid organic phase and a drug organic phase; s2, under an ultrasonic condition, successively mixing the water phase, the drug organic phase and the lipid organic phase in a microreactor through a microfluidic technology to form lipid nanoparticles, so as to obtain a crude sample containing the lipid nanoparticles; s3, diluting the crude sample by using a PBS (Phosphate Buffer Solution), and standing to obtain a sample diluent; s4, the sample diluent is subjected to ultrafiltration concentration, a concentrated sample is obtained, and a lipid nanoparticle product loaded with the medicine components is obtained. By adjusting the mixing time of the lipid component phase and other two-phase solutions, the drug precipitation rate and the lipid component precipitation rate are flexibly regulated and controlled, the drug encapsulation efficiency is effectively improved, and industrial production is facilitated.

The invention provides an application of ginseng oil body in preparation of a medicine for preventing and / or treating colitis, and belongs to the technical field of ginseng seed oil. The detection shows that the oil core structure of the ginseng oil body mainly consists of oleic acid and linoleic acid, and is different from the triglyceride core of the oil body obtained from the existing oil crops. Through lipidomics detection and analysis, the phospholipid monomolecular layer has 335 phospholipids (positive ion mode) and 269 phospholipids (negative ion mode). Through proteomics detection and analysis, 24 kinds of Panax proteins are identified. The condition that the oil core of the ginseng oil body contains protopanaxatriol (PPT) is identified through high performance liquid chromatography-high resolution mass spectrometry. In-vitro detection shows that the ginseng oil body has anti-inflammatory and anti-oxidation effects.

Described herein are compositions, kits, and methods for potent delivery to a cell of a subject. The cell can be of a particular cell type, such as a basal cell. In some cases, the cell can be a lung cell of a particular cell type. Also described herein are pharmaceutical compositions comprising a therapeutic or prophylactic agent assembled to a lipid composition. The lipid composition can comprise an ionizable cationic lipid, and a selective organ targeting lipid. The lipid composition can further comprise a phospholipid. Further described herein are high-potency intravenous dosage forms of a therapeutic or prophylactic agent formulated with a lipid composition.

The present disclosure provides lipid nanoparticles that are beneficially effective in the targeting of hepatic stellate cells with enhanced specificity. The lipid nanoparticles include five lipid components, including a permanently charged cationic lipid that is a quaternary ammonium lipid. The disclosure also provides pharmaceutical compositions and methods including the provided lipid nanoparticles.

The present disclosure provides lipid nanoparticles that are beneficially effective in the targeting of hepatic stellate cells with enhanced specificity. The lipid nanoparticles include five lipid components, including a permanently charged cationic lipid that is a quaternary ammonium lipid. The disclosure also provides pharmaceutical compositions and methods including the provided lipid nanoparticles.

A lipid-containing composition, by weight, includes phospholipids, and one or more of vegetable oil, medium-chain triglycerides, antioxidants, and sodium oleate. It has been verified that the various compositions provided by this invention competitively capture protein-bound toxoids in the blood, thereby achieving the purpose of clearing protein-bound toxoids from the blood, especially for patients with liver failure, and also alleviating oxidative stress in patients during dialysis treatment.

The invention belongs to the field of pharmaceutical preparations, and relates to a nano-liposome preparation based on phase transfer induced assembly and a preparation method thereof. The nano-liposome preparation comprises an active pharmaceutical ingredient, an amphiphilic lipid component and a lipid membrane structure regulator. The preparation method comprises the following steps: firstly, preparing active pharmaceutical ingredients into colloidal particles as a drug core; dispersing the core in an organic solvent containing a lipid component and a lipid membrane structure regulator to form an oil phase dispersion system; the preparation method comprises the following steps: preparing an oil phase system, then contacting the oil phase system with a water phase, carrying out phase transfer induced assembly to enable lipid to spontaneously coat a drug core on a water-oil interface and migrate to the water phase so as to form a nano-liposome with a lipid double-layer structure, and finally removing an organic solvent, thereby obtaining the nano-liposome. The method disclosed by the invention has the advantages of high drug loading capacity, strong universality, simple and convenient process, easiness in large-scale production and the like, and is suitable for efficient loading of various water-soluble drugs.

A biomarker for determining Kawasaki disease is identified by lipidomic analysis and mass spectrometry. With the use of the biomarker, we develop and provide a kit and a method capable of directly and objectively determining whether the subject suspected of having Kawasaki disease suffers from Kawasaki disease. A kit for determining Kawasaki disease, the kit including LOX-1 protein and / or part thereof having LAB-binding ability, the protein or part thereof being immobilized on a surface of a base material, is provided.

The application belongs to the field of biological medicine, and relates to a lipid component of a chimeric antigen receptor neutrophil targeting Her2 generated in vivo, a preparation method thereof and application in solid tumor treatment. The lipid nanoparticle is a double-targeted lipid nanoparticle, and the double targeting is realized by Ly6G antibody fragments and NEBP polypeptides. The lipid nanoparticle comprises a lipid component and mRNA encoding Her2-CAR and IFN-gamma. The mRNA encoding Her2-CAR and IFN-gamma is delivered by the lipid nanoparticle LNP, and is delivered to neutrophils in vivo and expresses Her2-CAR and IFN-gamma to generate CAR-neutrophils, so that the cumbersome step of editing immune cells in vitro is omitted, and potential adverse reactions caused by reinfusion of CAR-immune cells prepared in vitro into the body are avoided.

The invention relates to the field of genetic engineering medicine and vaccine manufacturing, in particular to a nucleic acid-small molecule medicine co-delivery system and a preparation method and application thereof. According to the nucleic acid-small molecule drug co-delivery system, lipid components serve as a carrier, the carrier encapsulates drug components, and the lipid components comprise cationic lipid, neutral phospholipid, cholesterol and PEG-lipid; the medicine component comprises a nucleic acid medicine and a small molecule medicine; the particle size of the nucleic acid-small molecule drug co-delivery system is 50-300 nm. Experiments prove that the nucleic acid-small molecule drug co-delivery system disclosed by the invention has a wide application prospect in the fields of anti-inflammation, immunoregulation and anti-tumor.

The invention discloses an imidazolyl lipid assembly as well as a preparation method and application thereof, and relates to the technical field of biomedical materials. The preparation method comprises the following steps: mixing diphenyl phosphate, alcohol and pyridine, and heating for reaction to obtain alkyl phosphate; mixing N, N-diethylethylenediamine, 5-imidazole formaldehyde and a solvent, carrying out a heating reaction in a protective atmosphere, then adding the alkyl phosphate, and continuing the heating reaction to obtain an imidazolyl lipid molecule; dissolving the imidazolyl lipid molecules in an organic solvent to obtain a mother solution; the imidazolyl lipid assembly is obtained from the mother liquor through a film hydration method. The imidazole-based lipid assembly constructed by the invention can utilize the imidazole group to destroy the normal structure of bacteria under the condition of no antibiotic load, and utilizes the catalytic action of the imidazole group to complete the destroy of a biological membrane matrix and an inflammation activation medium, so that the synergism of antibiosis and anti-inflammation is realized, and the imidazole-based lipid assembly has the effect of buffering local acidic pH.

The invention relates to a composition comprising a cell-free lipoaspirate-derived preparation comprising a lipid fraction and / or an aqueous fraction of a lipoaspirate and at least one biodegradable crosslinked hydrogel. The invention further relates to a device and a kit comprising the composition. The composition, the device and the kit can be generally applied for aesthetic treatment of soft-tissue loss or deficit.

The invention provides a lipidosome adjuvant system based on furanose type QS-21 saponin molecules and a preparation method. The lipidosome adjuvant system comprises lipidosome and the QS-21 saponin molecules, the lipidosome comprises a lipid bilayer formed by ionizable lipid, structural phospholipid and cholesterol, the QS-21 saponin molecule is in a furanose type and is loaded on the lipidosome, and the QS-21 saponin molecule is partially inserted into the lipid bilayer through hydrophobic triterpenoid aglycone of the QS-21 saponin molecule. The preparation method comprises the following steps: dissolving lipidosome components forming lipid bilayers in an organic solvent to form a lipid phase, dissolving furanose type QS-21 saponin molecules in an acidic aqueous phase buffer solution to form a QS-21 aqueous phase, mixing the lipid phase and the QS-21 aqueous phase, precipitating lipid, and self-assembling to form lipidosome nanoparticles loaded with furanose type QS-21 saponin molecules, and finally, purifying to remove the organic solvent and the unencapsulated QS-21 molecules. According to the invention, through well-designed lipid composition and a preparation process, furanose type QS21 molecules are stably integrated into the lipidosome.

This invention discloses a lipid composition, stock solution, preparation method, preparation system, and application for preparing broad-spectrum solvent-compatible liposomes. The lipid composition consists of HSPC, cholesterol, octadecylamine, and vitamin E polyethylene glycol succinate in specific proportions; it is dissolved in an aqueous organic solvent (such as ethanol) to form a lipid stock solution; the preparation system employs a three-channel intelligent control pump; in the preparation method, the above-mentioned lipid stock solution, an aqueous phase containing the target components (which can be pure water to 40% organic solvent-water solution), and a blank aqueous phase are injected into a microfluidic chip to generate a liposome dispersion, which is then purified. This invention overcomes the limitation of solvent polarity on liposome preparation, enabling the stable preparation of high-quality liposomes in a wide range of solvent systems. Experiments have shown that this liposome significantly enhances the stability and transdermal permeability of the encapsulated components, providing a universal, precise, and low-cost delivery platform for encapsulating various active ingredients.

The application discloses albumin site-directed modification lipid nanoparticles and preparation and application thereof, and relates to a kind of albumin site-directed modification lipid nanoparticles, which is prepared by synthesizing functionalized low molecular weight polyethylene glycol (PEG) lipid compound-maleimide derivative, together with the nucleic acid delivery lipid composition material usually used, to prepare nucleic acid-loaded lipid nanoparticles, then make the maleimide on its surface couple with the thiol group of albumin, to prepare the lipid nanoparticles with albumin site-directed modification on the surface.The application reduces the immunogenicity generated by the existing mRNA-loaded lipid nanoparticles outer layer covered PEG to the body, improves the related immune organ targeting of the nanoparticles, effectively delivers mRNA to lymph nodes to induce anti-tumor effect, and lays a foundation for further developing it as a new type of vaccine that can activate the immune system to produce anti-tumor effect.

The present application relates to the technical field of biological medicine, in particular to a lipid metabolite combination for early diagnosis of VKH and application thereof, by obtaining plasma samples of patients with initial acute stage (early stage) VKH syndrome and healthy controls, and constructing sample-full lipid quantitative expression matrix, screening differential lipids through PCA unsupervised analysis and OPLS-DA supervised model, further screening lipids with high diagnostic performance by using elastic net logistic regression model, finally obtaining a diagnostic marker combination composed of 25 lipid metabolites, solving the technical problems of existing VKH diagnosis technology, such as invasiveness, insufficient sensitivity and stability of protein marker detection, limited diagnostic efficiency, lack of systematicness and standardized process in lipidomics research, achieving the effect of non-invasive, efficient, high sensitivity and high specificity of early auxiliary diagnosis of VKH syndrome, and providing objective and reliable technical means for precise identification of atypical cases and large-scale clinical screening.

The invention provides an abdominal aortic aneurysm early prediction model construction method, system and device and a medium. According to the method, a balanced research queue is constructed through fusion of multi-modal data (ultrasonic images, biochemical indexes and lipidomics) and tendency score matching, so that the accuracy of early risk identification of the abdominal aortic aneurysm and the model robustness are remarkably improved; furthermore, on the basis of a risk migration strategy, the discrimination capability of the complex deep learning model is migrated to a simplified logistic regression model which only needs a simplest lipid feature set and basic demographic information, so that high prediction performance is maintained, model lightweight, parameter immobilization and clinical interpretability are realized, the detection cost and the operation complexity are greatly reduced, and the detection efficiency is improved. A high-precision risk prediction technology can be conveniently deployed in a basic medical scene, and finally an abdominal aortic aneurysm early screening solution with high precision, high interpretability and wide applicability is formed.

The present invention aims to provide a cell culture substrate suitable for cell culture. In particular, it aims to provide a cell culture substrate that can efficiently produce cultured meat. [Solution] The cell culture substrate according to the present invention comprises a three-dimensional structure composed of proteins that facilitate cell adhesion and lipids that provide a hydrophobic environment conducive to cell adhesion. Therefore, animal cells can be cultured using a cell culture carrier equipped with this three-dimensional structure. Furthermore, in the cell culture substrate of the present invention, the sum of the dry mass of proteins and lipids in the dry mass of the cell culture substrate is 80% by mass or more, so animal cells adhere easily to the cell culture substrate, preventing unintended inhibition of culture. Based on the above, the cell culture substrate according to the present invention is a cell culture substrate suitable for cell culture.

The invention provides a nucleic acid lipid nano-carrier as well as a preparation method and application thereof. The invention firstly provides a nano-carrier composition for a nucleic acid drug, and the nano-carrier composition comprises the following lipid components by taking the total molar weight of lipid in the composition as 100%: greater than or equal to 40% and less than or equal to 50% of ionizable lipid; the PEG modified lipid is greater than or equal to 0.5% and less than or equal to 3.0%; steroid: more than or equal to 30% and less than or equal to 44.5%; and more than 15% and less than 22% of auxiliary phospholipids. The invention also provides application of the composition in preparation of a nucleic acid drug nano-carrier and the prepared nucleic acid-loaded drug. The nucleic acid drug nano-carrier disclosed by the invention can target a treatment part, and a non-liver-targeted lipid nano-carrier has low liver metastasis.

The present disclosure provides a lipid compound, which can be used in combination with other lipid components, such as neutral lipids, cholesterol, and polymer-lipid conjugates, to form lipid nanoparticles for delivery of therapeutic agents (e.g. nucleic acid molecules) for therapeutic or prophylactic purposes, comprising vaccination. Also provided herein is a lipid nanoparticle composition comprising the lipid compound.

There is provided a vegetable-based lipid composition comprising high levels of at least three different long-chain polyunsaturated fatty acids (typically as fatty acid esters). The compositions typically contain DHA as the principal long-chain polyunsaturated fatty acid. The composition is obtainable from a single source by conventional processing methods, and has improved stability properties.

The present invention relates to a method for preparing lipid nanoparticles, the method comprising a step of mixing an organic solution containing a lipid component with an aqueous solution containing a nucleic acid component, thereby forming lipid nanoparticles, wherein the aqueous solution is an aqueous solution having a neutral pH, changes such as the change in the size of lipid nanoparticles due to a change in the pH of a solvent during the preparation of lipid nanoparticles is suppressed, thereby enabling the size of nanoparticles to be kept small, and nanoparticles can be prepared containing, as a component of lipid nanoparticles, a material that is unstable under acidic pH conditions.

The invention discloses a method for identifying a rice grain filling stage process based on starch particle surface lipid. The method specifically comprises the following steps: taking rice starch at different stages of a filling stage as a research model, extracting surface lipids of starch particles at normal temperature by using an organic reagent (n-propyl alcohol: water), and detecting and analyzing the relative content of the surface lipids of the starch particles by using lipidomics. The identified symbolic lipid shows a remarkable dynamic change trend in the rice grain filling stage, and the increase of the relative content of the symbolic lipid can accurately indicate the stage progress of rice grain filling. Through quantitative analysis on the symbolic lipids, the filling state of the rice can be accurately evaluated from the molecular level, so that a scientific basis is provided for determining the duration of the filling period of the rice grains.